B. Metzler seel. Sohn & Co. Holding AG Buys Shares of 22,673 Moderna, Inc. (NASDAQ:MRNA)

B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 22,673 shares of the company's stock, valued at approximately $1,515,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in MRNA. Ashton Thomas Private Wealth LLC purchased a new stake in shares of Moderna during the 2nd quarter valued at $26,000. Family Firm Inc. purchased a new stake in Moderna in the second quarter valued at about $33,000. Bank & Trust Co acquired a new stake in Moderna in the second quarter worth about $36,000. Hanseatic Management Services Inc. purchased a new stake in shares of Moderna during the second quarter worth about $48,000. Finally, Plato Investment Management Ltd increased its holdings in shares of Moderna by 230.4% during the second quarter. Plato Investment Management Ltd now owns 413 shares of the company's stock valued at $49,000 after acquiring an additional 288 shares in the last quarter. Hedge funds and other institutional investors own 75.33% of the company's stock.

Moderna Stock Performance

NASDAQ MRNA traded up $2.86 during mid-day trading on Friday, reaching $41.11. 13,410,793 shares of the stock were exchanged, compared to its average volume of 9,553,876. The company has a market capitalization of $15.82 billion, a P/E ratio of -7.06 and a beta of 1.69. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39. The business's 50 day moving average is $54.96 and its 200-day moving average is $94.09. Moderna, Inc. has a 1 year low of $35.80 and a 1 year high of $170.47.

Moderna (NASDAQ:MRNA - Get Free Report) last posted its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.89) by $1.92. The business had revenue of $1.90 billion for the quarter, compared to analyst estimates of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The company's revenue for the quarter was up 3.8% on a year-over-year basis. During the same period in the prior year, the company posted ($1.39) EPS. On average, equities research analysts forecast that Moderna, Inc. will post -9.44 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

MRNA has been the subject of a number of recent analyst reports. Barclays lowered their target price on shares of Moderna from $125.00 to $111.00 and set an "overweight" rating for the company in a research note on Friday, November 8th. Bank of America lowered their price objective on shares of Moderna from $130.00 to $110.00 and set a "neutral" rating for the company in a research note on Friday, September 13th. UBS Group dropped their price objective on shares of Moderna from $140.00 to $108.00 and set a "buy" rating on the stock in a report on Thursday, October 24th. Hsbc Global Res upgraded Moderna from a "hold" rating to a "strong-buy" rating in a research note on Monday, November 18th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Moderna in a research report on Friday, November 8th. Three investment analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Moderna has a consensus rating of "Hold" and a consensus target price of $84.00.

Insider Activity

In related news, CFO James M. Mock sold 1,321 shares of Moderna stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total value of $104,874.19. Following the sale, the chief financial officer now owns 8,600 shares of the company's stock, valued at approximately $682,754. This trade represents a 13.32 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 2,930 shares of company stock worth $217,170 over the last three months. 15.70% of the stock is currently owned by corporate insiders.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.